Overview of Melanoma

First degree relatives of individuals with Melanoma are at increased risk of developing skin cancers.

Keytruda treatment for melanoma improves survival, treats CNS disease and may be most effective when used in combination

Ocular melanoma is an uncommon cancer of the eye requiring aggressive treatment by specialized physicians.

FDA grants "Breakthrough Therapy Designation" for Bempegaldesleukin + Opdivo for previously untreated advanced Melanoma

Genomic testing should be performed in all patients-precision medicines reduce recurrences and prolong survival.

Keytruda immunotherapy + BRAF- MEK Inhibitors combo further delays melanoma progression compared BRAF-MEK alone.